Profile data is unavailable for this security.
About the company
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
- Revenue in DKK (TTM)401.54m
- Net income in DKK143.80m
- Incorporated1997
- Employees171.00
- LocationChemometec A/SGydevang 43ALLEROED 3450DenmarkDNK
- Websitehttps://chemometec.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellaVision AB | 464.71m | 92.66m | 3.90bn | 223.00 | 42.06 | 7.83 | 32.65 | 8.39 | 5.92 | 5.92 | 29.69 | 31.81 | 0.757 | 1.68 | 8.45 | 3,106,469.00 | 15.09 | 15.30 | 17.34 | 18.24 | 67.52 | 69.03 | 19.94 | 19.98 | 2.21 | 66.29 | 0.0688 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
Surgical Science Sweden AB | 552.46m | 136.44m | 4.05bn | 265.00 | 29.68 | 1.35 | 23.31 | 7.33 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Revenio Group Oyj | 721.11m | 141.79m | 5.43bn | 216.00 | 37.86 | 7.26 | 31.71 | 7.53 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
ChemoMetec A/S | 401.54m | 143.80m | 6.04bn | 171.00 | 41.98 | 12.10 | 37.21 | 15.03 | 8.26 | 8.26 | 23.07 | 28.66 | 0.6982 | 0.8064 | 6.01 | 2,448,421.00 | 25.00 | 30.43 | 29.69 | 38.99 | 78.85 | 79.44 | 35.81 | 34.17 | 3.37 | -- | 0.0118 | 46.90 | 3.74 | 31.58 | 12.04 | 57.88 | 19.91 | -- |
Arjo AB (publ) | 7.28bn | 339.87m | 6.79bn | 6.71k | 21.41 | 1.37 | 6.68 | 0.9323 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
Biotage AB | 1.30bn | 154.84m | 8.40bn | 669.00 | 53.18 | 3.29 | 31.78 | 6.47 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
Xvivo Perfusion AB | 421.85m | 65.89m | 8.43bn | 148.00 | 123.00 | 6.42 | 77.96 | 19.99 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Investment Management (UK) Ltd.as of 27 Jun 2024 | 1.71m | 9.84% |
Invesco Advisers, Inc.as of 16 May 2023 | 881.14k | 5.06% |
Swedbank Robur Fonder ABas of 31 May 2024 | 754.00k | 4.33% |
Handelsbanken Fonder ABas of 31 May 2024 | 642.14k | 3.69% |
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 28 Mar 2024 | 621.41k | 3.57% |
Fj�rde AP-fondenas of 31 Dec 2023 | 600.00k | 3.45% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 571.56k | 3.28% |
Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 452.86k | 2.60% |
Norges Bank Investment Managementas of 31 Dec 2023 | 411.11k | 2.36% |
Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 380.00k | 2.18% |